Quilipta and Anesthesia Management
There are no specific perioperative concerns or discontinuation requirements for Quilipta (atogepant) before anesthesia, as it is a CGRP receptor antagonist for migraine prevention with no known effects on gastric emptying, metabolic function, or aspiration risk.
Key Clinical Points
The question appears to conflate Quilipta with combination diabetes medications. To clarify:
- Quilipta contains atogepant only - a CGRP receptor antagonist used for migraine prevention 1
- It is NOT empagliflozin/linagliptin - that combination is a separate diabetes medication containing an SGLT2 inhibitor and DPP-4 inhibitor 2
Perioperative Management of Quilipta
Continue Quilipta through the perioperative period without interruption. The medication has no documented interactions with anesthesia and poses no specific perioperative risks related to:
- Gastric emptying or aspiration
- Metabolic derangements
- Ketoacidosis
- Hemodynamic instability
Safety Considerations
The only relevant perioperative concern is hypersensitivity reactions, which can include anaphylaxis and dyspnea 1. These reactions:
- Can occur days after administration
- Require immediate discontinuation if they occur
- Are managed with standard anaphylaxis protocols
Practical Recommendations
- No preoperative discontinuation needed
- No special fasting requirements beyond standard NPO guidelines
- Continue usual dosing schedule (10 mg, 30 mg, or 60 mg once daily)
- Resume immediately postoperatively once oral intake is tolerated
If the Question Concerns SGLT2 Inhibitors
If you are actually asking about an SGLT2 inhibitor-containing medication for a diabetic patient, the management differs completely:
SGLT2 inhibitors must be omitted the day before and the day of surgery to prevent euglycemic diabetic ketoacidosis 3. This provides a minimum 36-48 hour gap before the procedure, which reduces (but does not eliminate) the risk of perioperative ketoacidosis.
Critical Mitigation Strategies for SGLT2 Inhibitors
- Maintain adequate hydration
- Avoid prolonged fasting periods
- Monitor glucose and ketones perioperatively
- Consider glucose-containing IV fluids if prolonged fasting is unavoidable
- Restart only when eating/drinking normally AND capillary ketones < 0.6 mmol/L 3
The risk of perioperative DKA with SGLT2 inhibitors is 1.02 per 1000 patients versus 0.69 per 1000 without these medications (OR 1.48) 3, and euglycemic ketoacidosis can occur even in non-diabetic patients taking these drugs 3.